Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

163.53 -5.04 (-2.99%)
Streaming Delayed Price Updated: 1:56 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of... 
Via Benzinga
3 Biotech Stocks to Buy Before the Breakout
Explosive growth and rapid innovation lie ahead for these three biotechnology stocks, making them the ones to watch. 
Via InvestorPlace
Expert Ratings for Krystal Biotech
Via Benzinga
What Will AbbVie Buy Next?
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
Krystal Biotech Inc. (NASDAQ: KRYS) is a Stock Spotlight on 6/8
Via Investor Brand Network
Up 48% in 2023, Is This Biotech Stock a Buy?
How much longer can this biotech's run last? 
Via The Motley Fool
2 Soaring Stocks With More Upside Potential
Are these mid-cap stocks giants in the making? 
Via The Motley Fool
Arbutus Appoints Two New Executives
From Arbutus Biopharma Corporation
Via GlobeNewswire
Top 5 Health Care Stocks That Could Sink Your Portfolio This Quarter
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Krystal Clear: Krystal Biotech Clears Resistance in Good Volume
Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem. 
Via MarketBeat
Exposures Product Safety
Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™
From Option Care Health, Inc.
Via GlobeNewswire
Why Shares of Krystal Biotech Are Rising Monday
The company is moving quickly to market its newly approved therapy. 
Via The Motley Fool
Analyst Expectations for Krystal Biotech's Future
Via Benzinga
Expert Ratings for Krystal Biotech
Via Benzinga
Unlocking a $750 Million Opportunity: Krystal Biotech's Vyjuvek and its Potent Impact on Dystrophic Epidermolysis Bullosa Treatment
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for treating patients six months of age or older with  
Via Benzinga
Krystal Biotech Inc. (NASDAQ: KRYS) Highlighted for Surprising Price Action
Via Investor Brand Network
FDA Approves First Redosable Gene Therapy, Krystal Biotech's Treatment For Skin Blistering Disorder
The FDA approved Krystal Biotech Inc's (NASDAQ: KRYS) Vyjuvek (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic  
Via Benzinga
NVIDIA To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Needham cut the price target for Wix.com Ltd. (NASDAQ: WIX) from $125 to $120. Needham analyst Bernie McTernan maintained a Buy rating. Wix.com shares dropped 3.2% to close at $78.09 on Friday. 
Via Benzinga
Dentsply Sirona, Chico's FAS, Kontoor Brands And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping more than 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Krystal Biotech Epidermolysis Bullosa Study Data Published In New England Journal Of Medicine
Via Benzinga
2 Risky Stocks That Could Soar in 2023
These "exciting" companies aren't for everyone. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
Krystal Biotech's Subsidiary Posts Durability Data For Fine Line, Wrinkles
Via Benzinga
Recap: Krystal Biotech Q3 Earnings
Krystal Biotech (NASDAQ:KRYS) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period. 
Via Benzinga
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
Biotech is one of the safest, recession-proof sectors on the market. It's why we're going after the hottest biotech stocks in the New Year. 
Via InvestorPlace
SolarEdge To Rally 54%? Plus This Analyst Predicts $1,335 For Mettler-Toledo International
Goldman Sachs raised the price target on Mettler-Toledo International Inc. (NYSE: MTD) from $1,120 to $1,335. Goldman Sachs analyst Matthew Sykes upgraded the stock from Sell to Neutral. Mettler-Toledo... 
Via Benzinga
Cigna To $335? Plus This Analyst Slashes PT On Six Flags Entertainment By 25%
  SVB Leerink raised the price target on Cigna Corporation (NYSE: CI) from $305 to $335. Cigna shares rose 0.7% to close at $324.37 on Monday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.